Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates
- First Close of Series B financing raises €10 million
- Meiji Seika Pharma Co., Ltd joins as new international investor
- Proceeds will accelerate preclinical and clinical development of its broad-spectrum influenza vaccine candidates
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced the successful first close of its Series B financing, raising €10 million from new and existing investors.
The funds secured from Meiji Seika Pharma, new and existing investors, combined with non-diluted funding, will support the continued preclinical and clinical development of OVX836, Osivax’s broad-spectrum influenza vaccine candidate. This includes a Phase 2b field efficacy study (NCT05569239), designed to evaluate OVX836 against placebo in a large cohort of 2,850 participants across multiple international sites. The study represents a significant step in advancing the science of influenza prevention beyond conventional approaches.